Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Is Emblem Corp. The Most Undervalued Stock Amongst The Canadian Licensed Producers?

Jul 20, 2018 • 12:37 AM EDT
Cannabis (1).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

In 2018, Emblem Corp. (EMC.V) (EMMBF) has been nothing short of an execution story and this comes after the company replaced its CEO. We are favorable on the continued execution and consider Emblem to be one of the most undervalued Canadian cannabis companies.

In the last month, emblem has significantly advanced its story and we are favorable on the recent developments. From a recreational supply agreement in Alberta to a joint venture in Germany, Emblem has been laser focused on growth and this is a stock that investors need to keep an eye on.

Signs Recreational Supply Agreement and Expands to Germany

In early July, Emblem’s subsidiary, Emblem Cannabis Corporation, completed an agreement with the Alberta Gaming, Liquor & Cannabis Commission (AGLC) to supply high quality cannabis products for the province’s recreational marijuana market.

In late June, Emblem announced the formation of a joint venture with German pharmaceutical wholesaler Acnos Pharma GmbH for the purpose of exporting Emblem branded cannabis products from Canada and importing them into Germany.  The joint venture will operate under the name Emblem Germany and will be 60% owned by Emblem, subject to the completion of definitive agreements.

Subject to the entering into of definitive agreements, Emblem will supply the joint venture with cannabis oil for sale to German pharmacies, wholesalers and clinical labs for medical purposes.  The companies expect to commence export sales to Germany in 2019.

This is a significant relationship and places Emblem branded products in one the most exciting markets. In early 2017, Germany legalized medical marijuana and represents a massive opportunity, with a population north of 80 million. Germany will also provide Emblem with a stepping stone to other European markets and we are favorable on this relationship.

Once Emblem’s new 30,000 square foot Good Manufacturing Practices (GMP)-certified extraction facility is complete, the Canadian cannabis products will be able to significantly increase its extract and derivative product output to meet the expected demands of the German market.

An Attractive Focus on the Smokeless Product Market

Emblem is an undervalued Canadian cannabis producer that is in the middle of a major expansion. We are bullish on this initiative as it will significantly benefit company fundamentals and are monitoring how the team continues to execute.

We are favorable on the focus on the cannabis extract market and view this as a major value driver for the company. Demand for cannabis extracts continues to increase and we expect the trend toward smokeless products to become even more significant over the next few years. Since inception, Emblem has been laser focused on this opportunity and we excited by the growth potential.

In mid-May, Emblem and Canntab Therapeutics Limited (PILL.CN) received Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids, representing significant progress in the companies partnership to develop long-acting cannabis formulations.

Canntab brought equipment to Emblem’s Paris, Ontario facility and started making the first batch of the products using its patented technology and proprietary processes. This initial batch will undergo rigorous testing both internally by Emblem and Canntab and externally by third-party laboratories. Upon achievement of the product‘s target design criteria, the companies intend to submit a full dossier to Health Canada for review and approval.

An Undervalued Opportunity

We think the new management team at Emblem has been executing flawlessly and we find the valuation to be very attractive. As the company continues to execute, fundamentals will continue to improve, and we expect the market to respond favorably to this.

We are favorable on the improved distribution via an agreement with Shoppers Drug Mart as well as the relationship with companies like Fire and Flower, a retail cannabis-lifestyle brand and store concept.

When compared to its peers, Emblem is very attractively valued, and we think the market underestimates its potential. We are excited by the recent developments and investors need to keep an eye on this one.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.